Editas Medicine, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $40.5M | $32.3M | $78.1M | $19.7M | $25.5M |
| Research and development | $90.0M | $199.2M | $177.7M | $175.0M | $142.5M |
| Operating expenses | $200.5M | $283.5M | $247.3M | $245.7M | $218.7M |
| Operating income | -$160.0M | -$251.2M | -$169.2M | -$225.9M | -$193.1M |
| Interest expense | $2.1M | $0 | — | — | — |
| Income tax expense | $0 | $0 | $0 | $0 | $0 |
| Net income | -$160.1M | -$237.1M | -$153.2M | -$220.4M | -$192.5M |
| Balance Sheet | |||||
| Cash and equivalents | $146.6M | $131.5M | $123.7M | $141.5M | $203.5M |
| Current assets | $163.9M | $289.3M | $340.8M | $356.8M | $507.3M |
| Total assets | $186.5M | $341.6M | $499.2M | $514.3M | $677.5M |
| Current liabilities | $46.2M | $77.2M | $63.2M | $60.1M | $46.9M |
| Total liabilities | $159.2M | $207.3M | $150.1M | $153.6M | $123.8M |
| Stockholders' equity | $27.3M | $134.3M | $349.1M | $360.7M | $553.6M |
| Cash Flow Statement | |||||
| Cash from operations | -$165.2M | -$210.3M | -$132.2M | -$177.3M | -$163.8M |
| Depreciation and amortization | $5.3M | $5.8M | $6.1M | $6.3M | $5.1M |
| Stock-based compensation | $10.0M | $21.4M | $19.8M | $29.3M | $43.4M |
| Capital expenditure | $607,000 | $8.8M | $4.7M | $4.1M | $8.0M |
| Free cash flow | -$165.8M | -$219.1M | -$136.9M | -$181.5M | -$171.8M |
| Impairments | $3.8M | $0 | $0 | $0 | $0 |
Shares outstanding 97.9M · Free float 93.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.